Article Text

Download PDFPDF

Lung clearance index in CF: a sensitive marker of lung disease severity
  1. Jane C Davies1,2,3,
  2. Steve Cunningham3,4,
  3. Eric W F W Alton1,3,5,
  4. J A Innes3,6
  1. 1
    Department of Gene Therapy, Imperial College, London, UK
  2. 2
    Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK
  3. 3
    UK Cystic Fibrosis Gene Therapy Consortium, UK
  4. 4
    Department of Paediatric Respiratory Medicine, Hospital for Sick Children, Edinburgh, UK
  5. 5
    Department of Respiratory Medicine, Royal Brompton Hospital, London, UK
  6. 6
    Respiratory Unit, Western General Hospital, Edinburgh, UK
  1. Dr J C Davies, Department of Gene Therapy, Imperial College, London, UK; j.c.davies{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Despite airways which are thought to be normal at birth, 90% of patients with cystic fibrosis (CF) ultimately die from respiratory complications of the disease. The steps involved in the progressive destruction of the airways, and strategies aimed at limiting these processes, are therefore major areas of research. For both research and clinical purposes, measures of lung involvement should ideally be (1) sensitive enough to detect abnormalities early and directly reflect changes in disease severity, either naturally occurring or in response to interventions; (2) feasible and reproducible in all age groups; and (3) repeatable over time.

With regard to the first of these criteria, there is increasing concern that conventional measures such as spirometry and chest radiography are insufficiently sensitive, particularly at the mild and moderate stages of disease. Use of these investigations has enabled a generation of clinicians to improve pulmonary status significantly, but these clinical improvements themselves serve to highlight the inadequacy of the tools we have available to assess them. In contrast to the situation several decades ago, forced expiratory volume in 1 s (FEV1) now falls too late and too slowly to be accepted unquestioningly as the gold standard. From bronchoscopic studies there is growing concern that, by the time routine spirometry is abnormal, a self-perpetuating infective and inflammatory process has taken hold within the lung that may be difficult to reverse.1 2 Furthermore, reports of …

View Full Text

Linked Articles